Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
AstraZeneca
Institut du Cancer de Montpellier - Val d'Aurelle
Institut du Cancer de Montpellier - Val d'Aurelle
National Cancer Institute (NCI)
Aminex Therapeutics, Inc.
University of Southern California
Nuvation Bio Inc.
Centre Hospitalier Universitaire de Besancon
Weill Medical College of Cornell University
Southwest Hospital, China
AHS Cancer Control Alberta
Chinese PLA General Hospital
BBB-Therapeutics B.V.
Xijing Hospital
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Rambam Health Care Campus
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Envita Medical Center, Inc.
TransMolecular
Thallion Pharmaceuticals